Last Updated: November 16, 2026

Details for Patent: 9,326,981

« Back to Dashboard


Which drugs does patent 9,326,981 protect, and when does it expire?

Patent 9,326,981 protects KYNMOBI and is included in one NDA.

This patent has forty-eight patent family members in twenty countries.

Summary for Patent: 9,326,981
Title:Sublingual apomorphine
Abstract:The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film.
Inventor(s):Anthony John Giovinazzo, David Bruce Hedden, Marc L. de Somer, Nathan John Bryson
Assignee: Sunovion CNS Development Canada ULC , Sumitomo Pharma America Inc
Application Number:US14/684,146
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

US Patent 9,326,981: Apomorphine Sublingual Film Claims, Exclusivity and Patent Landscape

US Patent 9,326,981 protects a Parkinson's disease treatment method using a multilayer, non-effervescent, mucoadhesive sublingual film containing an acid-addition salt of apomorphine. The principal commercial product associated with this technology is KYNMOBI, an apomorphine hydrochloride sublingual film approved by the FDA in 2020. The patent is method-of-treatment protection, not a broad composition claim.

The strongest infringement position requires proof of all core elements: Parkinson's treatment, an apomorphine-containing film, separate apomorphine and pH-neutralizing layers, mucoadhesion, non-effervescence, and sublingual contact. A competing apomorphine product delivered by injection, infusion, tablet, or a materially different film architecture would not fall within claim 1 solely because it uses the same active ingredient.

What does US Patent 9,326,981 protect?

The patent protects a specific drug-delivery system and its administration for Parkinson's disease. Claim 1 is the controlling independent claim.

Claim element Scope
Disease Parkinson's disease
Active ingredient Acid-addition salt of apomorphine
Dosage form Unit-dose film
Film architecture First layer with apomorphine particles and second layer with a pH-neutralizing agent
Physical properties Non-effervescent and mucoadhesive
Polymer requirement Film contains a mucoadhesive polymer
Route Sublingual administration
Administration step Film contacts sublingual mucosal tissue
Therapeutic result Apomorphine amount effective to treat Parkinson's disease

The claim is cumulative. Omitting any required limitation creates a potential non-infringement position, subject to claim construction and the doctrine of equivalents.

The claim does not require a particular brand, manufacturer, polymer, antioxidant, particle size, dose, or plasma concentration unless those limitations are added through dependent claims.

How broad is claim 1 of US 9,326,981?

Claim 1 is broad within the sublingual-film field but narrow compared with a general apomorphine patent.

Active ingredient scope

The phrase “acid addition salt of apomorphine” covers apomorphine salts formed with an acid. Claim 2 narrows the scope to apomorphine hydrochloride, the salt used in KYNMOBI. Claim 1 is not limited to hydrochloride and could reach other pharmaceutically acceptable acid-addition salts if they satisfy the remaining limitations.

The claim does not require a specific polymorph, particle morphology, assay, release rate, or excipient composition.

Film structure

Claim 1 requires at least two functional layers:

  1. A first layer containing apomorphine particles.
  2. A second layer containing a pH-neutralizing agent.

The claim does not expressly require the layers to be arranged in a particular order relative to the mucosa, although the specification and prosecution history could affect construction. Claim 16 adds a third layer positioned between the first and second layers.

This layered arrangement is important. A homogeneous single-layer film may avoid literal infringement if it does not contain the required first and second layers. A two-layer film in which the neutralizing agent is distributed throughout both layers may create a claim-construction issue rather than an automatic infringement finding.

Mucoadhesive and non-effervescent limitations

The film must be both mucoadhesive and non-effervescent. The non-effervescent limitation separates the claimed technology from dosage forms that generate gas through an acid-base reaction.

The mucoadhesive requirement is central to the claim. A rapidly dissolving oral strip that does not adhere to sublingual mucosa may present a stronger design-around position. The legal result would depend on how the patent defines mucoadhesion and whether the accused formulation has measurable adhesive behavior.

Administration limitations

Claim 1 is a method claim. It requires placing the film sublingually in the subject's mouth and contacting sublingual mucosal tissue. Manufacture, sale, or possession of the film alone does not satisfy every express limitation of the claim, although those activities may create liability under other patent theories, including induced or contributory infringement.

What do claims 2 through 16 add?

The dependent claims create narrower positions around formulation, dose, particle engineering, and pharmacokinetics.

Claim Added limitation Commercial or legal significance
2 Apomorphine hydrochloride Aligns directly with KYNMOBI's active salt
3 Antioxidant Covers stability-enhancing formulations
4 Permeation enhancer Targets improved transmucosal delivery
5 Glycerol monostearate Narrow excipient-specific claim
6 Effective particle size of 1 to 10 micrometers Covers particle engineering and dissolution behavior
7 Polysaccharide Adds a broad polymer-class limitation
8 2 to 40 mg apomorphine salt Broad dose range
9 12 to 30 mg Commercially relevant intermediate range
10 12 ± 3 mg Approximately 9 to 15 mg
11 22 ± 4 mg Approximately 18 to 26 mg
12 30 ± 5 mg Approximately 25 to 35 mg
13 35 ± 5 mg Approximately 30 to 40 mg
14 Organic base as pH-neutralizing agent Narrows neutralization chemistry
15 At least 3 ng/mL average plasma concentration within 20 minutes Adds a pharmacokinetic performance limitation
16 Third layer between first and second layers Protects a more complex multilayer construction

The dose claims have overlapping numerical ranges. Claims 10 through 13 are narrower than claim 8 but overlap one another at certain boundaries. For example, claim 12 covers approximately 25 to 35 mg, while claim 13 covers approximately 30 to 40 mg. A product at 32 mg could potentially fall within both claims if all other limitations are met.

Claim 15 is potentially difficult to enforce because it requires evidence of an average circulating plasma concentration in a defined time window. It may be more useful as a fallback claim than as the primary commercial claim.

What formulations are protected by US 9,326,981?

The patent protects formulations with the following combination:

  • Apomorphine particles in a film layer;
  • A separate layer containing a pH-neutralizing agent;
  • A mucoadhesive polymer;
  • A non-effervescent delivery system;
  • Sublingual administration for Parkinson's disease.

The dependent claims extend protection to formulations containing antioxidants, permeation enhancers, glycerol monostearate, polysaccharides, selected particle sizes, and specified dose bands.

The claims do not expressly require:

  • A particular film thickness;
  • A particular film area;
  • A specific dissolution time;
  • A particular brand name;
  • A particular manufacturing process;
  • A specific antioxidant;
  • A specific polysaccharide;
  • A particular pH value;
  • A specific release profile.

Those unclaimed features may still appear in the specification or related patent families, but they do not limit the claims as written unless incorporated through claim construction.

When does US Patent 9,326,981 lose exclusivity?

The patent's ordinary 20-year term is calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable terminal disclaimer. Public patent records identify a December 1, 2011 priority date for the relevant apomorphine film family. On that basis, the nominal statutory expiration is approximately December 1, 2032, before any patent-term adjustment. [1]

The exact enforceable expiration date must be determined from the USPTO patent-term record because patent-term adjustment can extend the term beyond the basic 20-year calculation. FDA patent-listing dates and patent expiration dates should not be treated as substitutes for the USPTO term calculation.

FDA regulatory exclusivity

KYNMOBI was approved under NDA 210875 on May 29, 2020, for the acute intermittent treatment of “off” episodes in adults with Parkinson's disease. [2] The product used the 505(b)(2) pathway rather than an ordinary ANDA pathway because the approved product introduced a distinct sublingual film presentation of apomorphine.

Apomorphine was not a new molecular entity in the United States. The principal FDA exclusivity relevant to KYNMOBI was therefore not five-year NCE exclusivity. The product received three-year exclusivity associated with new clinical investigations supporting the approved formulation and use. That exclusivity period did not extend to the 2032 patent expiration date.

Protection type Approximate date or status
FDA approval May 29, 2020
Three-year clinical-investigation exclusivity Approximately through May 29, 2023
US 9,326,981 nominal patent expiration Approximately December 1, 2032, before PTA
Patent protection after FDA exclusivity Primarily patent-based

What is the Orange Book status of US 9,326,981?

US 9,326,981 is associated with the KYNMOBI regulatory product and its sublingual apomorphine film technology. The relevant Orange Book analysis should distinguish three items:

  1. The approved NDA and its listed drug product.
  2. The patent number listed against the NDA.
  3. The patent-use code, if one is assigned.

A method patent can be listed in the Orange Book when it claims an approved method of using the drug. Its listing can require an ANDA or 505(b)(2) applicant to address the patent through certification.

For a listed method patent, an applicant may use a Paragraph IV certification if it asserts that the patent is invalid, unenforceable, or will not be infringed. A product seeking approval for a non-infringing use may use a section viii statement, where permitted, to carve out the patented method.

The commercial impact depends on the exact Orange Book use code. If the listed use code tracks treatment of Parkinson's “off” episodes with a sublingual film, a competing product seeking the same approved indication would face greater patent-certification exposure than a product targeting a different disease, route, or dosage form.

What Paragraph IV challenges and litigation affect KYNMOBI?

The claims supplied do not establish a Paragraph IV challenge, ANDA filing, or litigation outcome. FDA Orange Book data can identify listed patents, but it does not provide a complete litigation history.

A Paragraph IV challenge to US 9,326,981 would likely focus on four issues:

Anticipation and obviousness

A challenger could combine prior art relating to:

  • Apomorphine for Parkinson's disease;
  • Sublingual administration;
  • Mucoadhesive oral films;
  • Acid-base pH adjustment;
  • Multilayer film construction;
  • Particle-size reduction;
  • Transmucosal permeation enhancement.

The critical question would be whether one reference discloses the full combination, or whether a skilled person would have had a reason to combine the references with a reasonable expectation of success.

Written description and enablement

Potential challenges could address the breadth of “acid addition salt,” the range of mucoadhesive polymers, the range of pH-neutralizing agents, and the claimed plasma concentration. The more broadly the claims are construed, the more important the disclosure across the full claim scope becomes.

Infringement

A generic or follow-on product would need to assess whether its film has two separately identifiable layers and whether its formulation is non-effervescent and mucoadhesive. A design using a single homogeneous film, a non-mucoadhesive dosage form, or a different administration route could reduce literal infringement exposure.

Regulatory timing

If an ANDA or 505(b)(2) applicant filed a Paragraph IV certification before patent expiration, litigation could trigger a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and litigation events. The 30-month stay does not extend the patent term.

No biosimilar pathway applies because apomorphine is a small-molecule active ingredient. The relevant competitive pathways are ANDA, 505(b)(2), and potentially a full NDA.

Which companies are challenging the KYNMOBI patent estate?

The principal commercial parties are:

Company Role
Cynapsus Therapeutics Original developer of the sublingual apomorphine film platform
Sunovion Pharmaceuticals Acquired Cynapsus and commercialized KYNMOBI in the United States
Sumitomo Pharma Parent-company relationship associated with Sunovion operations
Generic and 505(b)(2) applicants Potential future challengers or follow-on developers

Sunovion agreed to acquire Cynapsus in 2016 for approximately $624 million in cash, subject to transaction terms. The transaction transferred control of the development program and its associated intellectual-property assets to Sunovion. [3]

The acquisition was a corporate transaction, not evidence that US 9,326,981 was licensed to a third-party generic manufacturer.

How strong is the patent estate for apomorphine sublingual film?

US 9,326,981 has meaningful commercial value because it combines active ingredient, dosage form, delivery route, formulation structure, and Parkinson's treatment in a single method claim.

Its principal strengths are:

  • Direct alignment with the approved KYNMOBI dosage form;
  • Multiple dependent claims covering dose and excipient variations;
  • Layered protection for particle size and pH neutralization;
  • A method claim that tracks the approved clinical use;
  • Patent duration materially longer than FDA clinical-investigation exclusivity.

Its principal vulnerabilities are:

  • The claim is limited to a film, not apomorphine generally;
  • The claim requires a specific multilayer arrangement;
  • “Mucoadhesive” and “pH-neutralizing agent” may require factual and claim-construction analysis;
  • The patent does not independently block injections, pumps, tablets, or all oral transmucosal products;
  • Some dependent claims may be vulnerable if the relevant formulation details were known in the oral-film field.

The estate is stronger against a direct KYNMOBI substitute than against a different apomorphine delivery platform.

How does KYNMOBI compare with competing apomorphine products?

Product or platform Active ingredient Route Dosage form Exposure to US 9,326,981
KYNMOBI Apomorphine hydrochloride Sublingual Mucoadhesive film Highest
APOKYN Apomorphine hydrochloride Subcutaneous injection Injectable solution Low under these claims
Apomorphine infusion systems Apomorphine Continuous infusion Pump or injectable formulation Low under these claims
Generic sublingual apomorphine film Apomorphine salt Sublingual Film Potentially high
Oral tablet or capsule Apomorphine or derivative Oral Solid dosage form Low under these claims
Nasal or buccal formulation Apomorphine Intranasal or buccal Spray, film, or tablet Depends on sublingual contact and film structure

The patent is not a monopoly over apomorphine treatment. It is a barrier around a particular sublingual film architecture and its use in Parkinson's disease.

What generic launch risks exist?

A generic or follow-on entrant faces the greatest risk if it:

  • Uses apomorphine hydrochloride;
  • Delivers the drug in a multilayer sublingual film;
  • Uses a mucoadhesive polymer;
  • Separates apomorphine from a pH-neutralizing agent by layer;
  • Targets the same Parkinson's disease “off” episode indication;
  • Uses overlapping dosage strengths;
  • Produces rapid plasma exposure comparable to the claimed pharmacokinetic result.

Possible design-around strategies include:

  1. Using a non-film dosage form.
  2. Using injection, infusion, nasal, or non-sublingual delivery.
  3. Developing a single-layer formulation.
  4. Avoiding a separate pH-neutralizing layer.
  5. Using a formulation that is not mucoadhesive.
  6. Targeting a different approved indication, where legally and commercially feasible.
  7. Using a different active ingredient or prodrug.

These approaches may create separate regulatory, formulation, or freedom-to-operate issues. Avoiding literal infringement of claim 1 does not eliminate risk under other patents in the family or related formulation patents.

What manufacturing and geographic IP barriers exist?

The patent is a United States right. It can block US manufacture, importation, sale, offer for sale, or use of an infringing product during the enforceable term. It does not directly control manufacturing or sales outside the United States.

For international programs, separate national family members must be assessed in Europe, Canada, Japan, and other target markets. Patent-term dates, claim scope, opposition history, supplementary protection certificates, and national prosecution outcomes can differ materially from the US position.

Manufacturing-related risks may also arise from unasserted or separately issued patents covering:

  • Film casting;
  • Layer lamination;
  • Drying conditions;
  • Particle-size control;
  • Apomorphine stabilization;
  • Packaging and moisture protection;
  • Dose uniformity;
  • Sublingual delivery performance.

US 9,326,981 itself is primarily a treatment-method patent. It does not, based on the claims supplied, provide a standalone manufacturing-process monopoly.

Key Takeaways

  • US 9,326,981 protects treatment of Parkinson's disease with a non-effervescent, mucoadhesive, multilayer sublingual apomorphine film.
  • Claim 1 is a method claim requiring all core formulation and administration limitations.
  • Claim 2 directly covers apomorphine hydrochloride.
  • Claims 8 through 13 cover dose ranges that overlap commercially relevant strengths.
  • Claim 15 adds a pharmacokinetic performance requirement of at least 3 ng/mL within 20 minutes.
  • The nominal patent expiration is approximately December 1, 2032, subject to patent-term adjustment.
  • KYNMOBI received FDA approval on May 29, 2020, and its regulatory exclusivity did not extend to the patent expiration date.
  • The patent creates the greatest risk for a direct generic or 505(b)(2) sublingual-film substitute.
  • Injectable, infused, tablet, and non-sublingual apomorphine products are outside the apparent literal scope of claim 1.
  • Apomorphine is a small molecule, so biosimilar regulation does not apply.
  • A complete freedom-to-operate assessment must include related family patents, Orange Book listings, prosecution history, and any later-issued continuation claims.

FAQs

Does US 9,326,981 cover all apomorphine products?

No. It is limited to a specific sublingual film method for treating Parkinson's disease. Injectable, infused, tablet, and other delivery systems generally do not satisfy the claim as written.

Can a single-layer apomorphine film avoid claim 1?

Potentially. Claim 1 requires a first layer containing apomorphine particles and a second layer containing a pH-neutralizing agent. A single-layer design may avoid literal infringement, although related patents and the doctrine of equivalents must be evaluated separately.

Does the patent require apomorphine hydrochloride?

No. Claim 1 covers an acid-addition salt of apomorphine generally. Claim 2 narrows the claim to apomorphine hydrochloride.

Is KYNMOBI protected by biologic exclusivity?

No. KYNMOBI contains apomorphine hydrochloride, a small-molecule active ingredient. Competition would proceed through ANDA or 505(b)(2) mechanisms, not a biosimilar application.

Does FDA approval automatically establish patent infringement?

No. FDA approval and patent infringement are separate questions. A product can receive regulatory approval while patent litigation, a Paragraph IV certification, a use carve-out, or a non-infringement dispute remains unresolved.

References

  1. United States Patent and Trademark Office. (2016). US Patent No. 9,326,981, Sublingual film compositions. U.S. Department of Commerce.
  2. U.S. Food and Drug Administration. (2020). KYNMOBI (apomorphine hydrochloride) sublingual film prescribing information.
  3. Sunovion Pharmaceuticals Inc. (2016). Sunovion to acquire Cynapsus Therapeutics. Corporate transaction announcement.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  5. U.S. Food and Drug Administration. (2024). Approved drug product exclusivity and patent information under the Hatch-Waxman Amendments.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,326,981

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.